The benefits of fusing uniquely attenuated IL-18 variants to an array of protein therapeutics with different mechanisms of action for oncology and autoimmune disease
Time: 12:00 pm
day: Conference Day Two
Details:
- Using a new mechanism of action to engineer IL-18 variants with optimal on-target activity
- The benefit of fusing an IL-18 variant to anti-PD1 to generate not only a targeted cytokine but also an enhanced checkpoint inhibitor
- The benefit of fusing an IL-18 variant with or without attenuated IL-15 to ADCC-competent antibodies and cell engagers in both oncology and autoimmune settings
